Genmab A (GMAB) Return on Capital Employed (2024 - 2026)

Genmab A (GMAB) posted Return on Capital Employed of 16.8% for Q1 2026, down 67.05% on a QoQ basis from 50.99% in Q3 2025.

Genmab A (GMAB) Return on Capital Employed (2024 - 2026) Analysis & Trends

Genmab A's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 16.8% for Q1 2026.

Quarterly Return on Capital Employed changed N/A year-over-year to 16.8% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.8% (changed N/A YoY) and the FY2025 annual result came in at 12.83%, changed N/A from the prior year.
Return on Capital Employed was 16.8% for Q1 2026 at Genmab A, down from 50.99% in the prior quarter.
Across five years, Return on Capital Employed topped out at 99.35% in Q4 2024 and bottomed at 16.8% in Q1 2026.
A 3-year average of 53.3% and a median of 48.52% in 2025 frame the typical range for Return on Capital Employed.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-31.80%
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.46%
4	NuCana	279.75 Bn	279.75 Bn	-	-68.47%
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	21.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	10.19%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-68.84%
10	Genmab A	1.89 Bn	366.92 Mn	831.00 Mn	16.80%

Download Data